schizandrin b has been researched along with Fatty Liver in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jia, ZH; Ko, KM; Pan, SY; Sun, N; Wang, XY; Yu, Q; Yu, ZL; Zhang, Y; Zhu, PL | 1 |
| Jang, MK; Jung, MH; Kim, JH; Kim, SH; Yun, YR | 1 |
| Jung, MH; Kim, JH; Yun, YR | 1 |
| Jang, MK; Jung, MH; Kim, JH; Park, MH; Yun, YR | 1 |
| Chu, ZS; Ko, KM; Pan, SY; Wang, XY; Xie, M; Yu, ZL; Zhang, Y; Zhao, J; Zhou, SF; Zhu, PL | 1 |
| Chan, PK; Chu, JH; Fong, WF; Pan, SY; Wang, H; Ye, Y; Yu, ZL | 1 |
| Dong, H; Fang, HY; Fong, WF; Ko, KM; Pan, SY; Xiang, CJ; Yu, ZL; Zhao, XY | 1 |
7 other study(ies) available for schizandrin b and Fatty Liver
| Article | Year |
|---|---|
Novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture.
Topics: Administration, Oral; Animals; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholesterol; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Hyperlipidemias; Lignans; Lipoproteins; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Time Factors; Triglycerides | 2013 |
Protective Effect of Gomisin N against Endoplasmic Reticulum Stress-Induced Hepatic Steatosis.
Topics: Acetyl-CoA Carboxylase; Animals; Cyclooctanes; Cytokines; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Fatty Acid Synthase, Type I; Fatty Liver; Glycerol-3-Phosphate O-Acyltransferase; Heat-Shock Proteins; Hep G2 Cells; Humans; Lignans; Liver; Mice, Inbred C57BL; Palmitic Acid; Polycyclic Compounds; Protective Agents; Transcription Factor CHOP; Triglycerides; Tunicamycin; X-Box Binding Protein 1 | 2016 |
Protective effects of gomisin N against hepatic steatosis through AMPK activation.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Anti-Inflammatory Agents; Cyclooctanes; Cytoplasm; Fatty Acids; Fatty Liver; Hep G2 Cells; Humans; Hydrocarbons, Fluorinated; Lignans; Lipogenesis; Liver; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Phosphorylation; Phytochemicals; Polycyclic Compounds; Protein Kinases; Sterol Regulatory Element Binding Protein 1; Sulfonamides; Triglycerides | 2017 |
Gomisin N inhibits adipogenesis and prevents high-fat diet-induced obesity.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; CCAAT-Enhancer-Binding Protein-beta; Clone Cells; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 6; Cyclins; Cyclooctanes; Diet, High-Fat; Down-Regulation; Fatty Liver; Histone-Lysine N-Methyltransferase; Lignans; Male; Mice; Mice, Inbred C57BL; Mitosis; Obesity; Polycyclic Compounds; PPAR gamma; Signal Transduction | 2017 |
Biochemical mechanism underlying hypertriglyceridemia and hepatic steatosis/hepatomegaly induced by acute schisandrin B treatment in mice.
Topics: Adipocytes; Adipose Tissue; Animals; Antineoplastic Agents, Phytogenic; Apolipoprotein B-48; Cell Size; Cholesterol; Cholesterol, VLDL; Cyclooctanes; Fatty Acids, Nonesterified; Fatty Liver; Hepatocyte Growth Factor; Hepatomegaly; Hypertriglyceridemia; Lignans; Liver; Male; Mice; Mice, Inbred ICR; Mitochondria; Polycyclic Compounds; Schisandra; Triglycerides | 2017 |
Inhibitory effect of schisandrin B on free fatty acid-induced steatosis in L-02 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cyclooctanes; Dose-Response Relationship, Drug; Fatty Acids, Nonesterified; Fatty Liver; Hepatocytes; Humans; Lignans; Lipid Metabolism; Liver; Membrane Proteins; Perilipin-2; Polycyclic Compounds; Sterol Regulatory Element Binding Protein 1; Treatment Outcome; Up-Regulation | 2011 |
Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.
Topics: Animals; Bile Acids and Salts; Cholesterol; Cholesterol, Dietary; Cyclooctanes; Disease Models, Animal; Dose-Response Relationship, Drug; Fatty Liver; Fenofibrate; Hypercholesterolemia; Hypolipidemic Agents; Lignans; Liver; Male; Mice; Mice, Inbred ICR; Polycyclic Compounds; Schisandra; Triglycerides | 2008 |